



Index

Note: Page numbers of article titles are in **boldface** type.

A

Acquired immune deficiency syndrome. See *AIDS*.

Acyclovir, in herpes zoster, 523

AIDS, 467

incidence of, 468

non-Hodgkin's lymphoma in, 541–542

reporting of cases of, 467

US surveillance data on, 468

American Dental Association, statement on water used in dental treatment, 553

Antiretroviral therapy, highly active, in HIV disease, 472–473, 477, 483

oral side effects of, 473, 474
toxicities associated with,
473–474

Antitubercular therapy, drug interactions in, 461

Arthritis, rheumatoid, and periodontitis, 584–585

treatment of, 585

Atherosclerosis, oral infections and, 575

B

Bacille Calmette-Guérin vaccine, 455

Bacteria, and systemic conditions with susceptibility to infection, 551

as building blocks of biofilms, 546

gram-negative heterotrophic, in water, 546

in dental waterlines, 548–549

entry into patient during dental procedures, 550

potential pathogenicity of, 549

oral, pneumonia and, 583–584

Barrier techniques, to prevent transmission of tuberculosis, 460–461

Biofilm(s). See also *Bacteria*.

and dental equipment design, 547–548

definition of, 546

nature of, 546–547

quorum sensing and, 547

Biopsies, for diagnosis of Creutzfeldt-Jakob disease, 507, 510–511

Blood products, Creutzfeldt-Jakob disease and, 502

Blood tests, for diagnosis of Creutzfeldt-Jakob disease, 506

Bovine spongiform encephalopathy, 493, 495

C

Cancrum oris. See *Noma*.

Candidiasis, oral pseudomembraneous, of buccal mucosa, 476

Cardiovascular disease, and periodontitis, 575–577

epidemiologic studies in, 576,
578–579, 580, 581

treatment of, 577

atherosclerosis in, 575

pathogenesis of, 576–577

risk factors for, 575–576

Central nervous system, transmissible spongiform encephalopathies and, 500, 502–503

Chemotherapy, in tuberculosis, 457

Chickenpox, 522

Chronic wasting disease, 495

Condyloma acuminatum, human papilloma virus-associated, 477, 482

Consumption. See *Tuberculosis*.

Creutzfeldt-Jakob disease, acquired, 498–501

Kuru, 498

transmission of, 501–502

vCJD, 499–501

as transmissible spongiform encephalopathy, 493

- Creutzfeldt-Jakob (*continued*)
associated with dental treatment,
503–504, 506, 507–508
clusters of, 504
diagnosis of, 505–509
identification of patients with, 508
in exposure to bovine spongiform
encephalopathy, 499
incidence of, 497
inherited, 498
clinical features of, 498
maxillofacial surgery in, 511
percutaneous exposure to fluids of
patients with, 510
persons at risk of developing, 509–510
possible causes of, 497–498
suspected cases of, management of,
509
symptoms of, 497
- Cystic fibrosis, susceptibility to infections
and, 551
- Cytomegalovirus, 540–541
as clinical marker for AIDS, 525
infection with, diagnosis of, 525
in immunosuppressed patients,
524
in neonates, 524
treatment of, 526
transmission of, 524

D

- Dental equipment, design of, biofilms and,
547–548
- Dental office, waterborne infections and,
545
- Dental treatment, complications from, in
HIV disease, 483–486
- Dental waterlines. See *Waterlines, dental*.
- Dentist(s), illness of, due to exposure to
contaminated dental treatment water,
552–553
transmission of tuberculosis by, 460
- Diabetes mellitus, and periodontitis,
585–586
treatment of, 586
- DNA oncogenic viruses, 535–541

E

- Electroencephalogram, for diagnosis of
Creutzfeldt-Jakob disease, 506
- Encephalopathy(ies), bovine spongiform,
493, 495

- scrapielike spongiform, 495
transmissible mink, 495
transmissible spongiform, agents,
inactivation of, 508
and dentistry, 503–504
animal, 493, 495
Creutzfeldt-Jakob disease as, 493
description of, 493
infection control and dental
treatment in, 505, 507–508,
509
infectious agents in, 494–495
orofacial manifestations of, 503
pathogenesis of, 501
prions and, **493–516**
treatment of, 503

- Endocarditis, infective, and oral bacteria,
577–583
bacteria causing, 582
conditions predisposing to, 582
dental treatment and, 583
pathogenesis of, 582
treatment of, 582

- Endotoxin, 551
results of exposure to, 551–552

- Enzyme-linked immunosorbent assay, 470

- Epstein-Barr virus, neoplasms associated
with, 538–539
oral hairy leukoplakia and, 527
transmission of, 539

- Epstein-Barr virus infection, chronic active,
526
malignancies associated with, 526–527
symptoms of, 526

- Erythema multiforme, recurring, recurrent
herpes simplex virus and, 520

- Ethambutol, in tuberculosis, 457
side effects of, 462

G

- Gingival disease, in HIV disease, 482, 483
- Gingivitis, acute necrotizing, incidence of,
560–561
precursor to noma, 559–560,
564–565

H

- Hairy leukoplakia, 476, 477
Epstein-Barr virus and, 527
- Head and neck, tuberculosis of, 453
- Health care facility, transmission of
tuberculosis in, risk categories for, 460

- Hepatitis, acute, hepatitis A as cause of, 436
 - causes of, 432
 - chronic, hepatitis B as cause of, 437
 - definition of, 431
 - human viral, advances in diagnosis and management of, **431–447**
 - chronic, 433–434
 - diagnosis of, 432–434
 - blood test for, 432–433
 - imaging techniques for, 432
 - liver function tests in, 433
 - HIV disease and, 475
 - pathogenesis of, 434–443
 - symptoms of, 431
 - systems affected by, 434
 - types of, 434
- Hepatitis A virus, acute hepatitis due to, 436
 - Centers for Disease Control and Prevention recommendation on, 435
 - countries with endemicity for, 435
 - infection with, management of, 444
 - pre-exposure prophylaxis and, 435
 - transmission of, factors increasing risk of, 435
- Hepatitis A virus vaccines, vaccination schedules for, 435, 436
- Hepatitis B virus, as cause of chronic hepatitis, 437
 - carriers of, 437
 - in hepatocellular carcinoma, 540
 - infection with, treatment of, 444
 - risk groups for, 437
 - transmission of, 436
- Hepatitis B virus vaccine, recommended doses of, 438
- Hepatitis C virus, chronic, 439
 - genotypes of, 440
 - incidence of, 439–440
 - infection with, management of, 444–445
 - neoplasms associated with, 540
 - risk groups for, 438, 439
 - transmission of, 438
- Hepatitis D virus, 441
 - and hepatitis B virus infection, 441
 - genotypes of, 441
- Hepatitis E virus, 441–442
 - infection with, management of, 445
- Hepatitis F virus, 442
 - infection with, management of, 445
- Hepatitis G virus, 442–443
 - infection with, management of, 445
- Hepatocellular carcinoma, viruses in development of, 540
- Herpes labialis, recurrent, 519–520
- Herpes simplex infections, diagnosis of,
 - cytology smears for, 521
 - immunomorphologic tests for, 521
 - serologic tests for, 522
 - virologic tests for, 520–521
- primary, 518–519
- recurrent, 519–520
- Herpes simplex virus(es), 540–541
 - types of, 518
- Herpes zoster, 522–524
 - acyclovir in, 523
 - and postherpetic neuralgia, 523–524
 - in immunocompromised patients, 523
 - symptoms of, 523
- Herpesvirus 6, human, 527
 - in immunocompromised patients, 527–528
 - treatment of, 528
- Herpesvirus 7, human, 528–529
- Herpesvirus-6B, roseola and, 527
- Herpesvirus infections, update on, **517–532**
- Herpesvirus type 8, neoplasia associated with, 539–540
- Herpesviruses, characteristics of, 517–518
- HIV, in neoplasms, 541–542
- HIV-associated Kaposi's sarcoma, oral
 - mucosal lesions of, 539
 - prevalance of, 541
- HIV disease, **467–492**
 - and tuberculosis, 454–455
 - antiretroviral drug-resistant
 - transmission of, 474
 - clinical staging of, 471
 - course of, and laboratory monitoring of, 471
 - dental treatment considerations in, 483–486
 - dentists in diagnosis of, 470
 - diagnosis of, 470
 - hepatitis viral infections with, 475
 - medical management of, 472–475
 - occupational exposure to, 469
 - opportunistic disease and, prevention and treatment of, 474–475
 - oral mucosal lesions in, and
 - periodontal disease, 475–482
 - oral opportunistic diseases and, 478–481

- HIV disease, (*continued*)
 pathogenesis of, 469–470
 reporting of cases of, 467
 salivary gland dysfunction in, 477–482
 suppression of HIV viremia and,
 472–475
 testing for, 470
 transmission of, 469
- Human immunodeficiency virus. See *HIV disease*.

I

- Illness, human, in exposure to contaminated dental treatment water, 552–553
- Infection(s), aerosolized, protection against inhalation of, 461
 biofilm-mediated, 547
 oral, and systemic diseases, **575–598**
 waterborne, dental office and, 545
- Isoniazid, in tuberculosis, 457
 side effects of, 461, 462

K

- Kaposi's sarcoma, 528
 epidemiologic forms of, 539
 HIV-associated, oral mucosal lesions of, 539
 prevalence of, 541
 malignant tumors induced by, 529
 pathogenesis of, 540
 sexual transmission of, 529
- Kaposi's sarcoma-associated herpesvirus, neoplasia associated with, 539–540
- Koch's postulates, 533
- Kuru, 498

L

- Leukoplakia, hairy, 476, 477
 Epstein-Barr virus and, 527
- Lip, recurrent herpes simplex infection of, 519–520
- Low birth weight, periodontitis, 586–590
- T-Lymphotropic 1 virus, human, neoplasia and, 541

M

- Magnetic resonance imaging, for diagnosis of Creutzfeldt-Jakob disease, 507
- Malnutrition, chronic, noma and, 565

- Masks, to prevent transmission of tuberculosis, 461
- Maxillofacial surgery, in Creutzfeldt-Jakob disease, 511
- Measles, noma and, 564, 565
- Mink encephalopathy, transmissible, 495
- Mycobacterium tuberculosis*, 449, 450

N

- Neonates, infection with cytomegalovirus, 524
- Neoplasm(s), associated with Epstein-Barr virus, 538–539
 associated with hepatitis C virus, 540
 associated with herpesvirus type 8, 539–540
 associated with Kaposi's sarcoma-associated herpesvirus, 539–540
 epidemiology pattern of, 534
 growth of, viruses and, **533–543**
 HIV in, 541–542
 human papillomaviruses and, 535–536
 human T-lymphotrophic 1 virus and, 541
 pathogenesis of, 534–535
 viral etiology of, criteria for establishing, 533
 viruses linked to, 534
- Neuralgia, postherpetic, herpes zoster and, 522–524
- Noma, as forgotten disease, **559–573**
 clinical presentation of, 561–563
 description of, 559
 diagnosis of, 562–563
 etiology and pathogenesis of, 563–567
 history of, 559–560
 incidence of, 560
 initial oral lesions and, 561
 lesions of, microbiota of, 565–566
 reconstructive surgery in, 568–569
 risk factors for acquiring, 564–565
 social and cultural aspects of society of source, 567
 survivors of, disfigurements in, 563
 treatment of, 567–569
 trigger organisms of, 566
 trismus associated with, 563, 567, 568
 World Health Organization noma network and, 569–570

Noma neonatorum, 561

Non-Hodgkin's lymphoma, in AIDS, 541–542

O

-
- Occupational exposure, to contaminated dental treatment water, 552
- Oral fluids, testing for antibodies, in diagnosis of HIV disease, 470
- Oral infections, and systemic diseases, **575–598**
- Oral mucosal lesions, HIV-associated, and periodontal disease, 475–482
of HIV-associated Kaposi's sarcoma, 539
of tuberculosis, 453–454

P

-
- Papillomaviruses, human, 535–538
and neoplasia, 535–536
lesions of, cells of, 537
malignant potential of, 536
replication of, 536
- Pathogens, waterborne, and dental waterlines, **545–557**
- Patient(s), illness of, due to exposure to contaminated dental treatment water, 552–553
transmission of tuberculosis to, 460
with tuberculosis, management of, 458–462
- Periodontal disease(s), and HIV-associated oral mucosal lesions, 475–482
in HIV disease, 482, 483
systemic diseases influencing, 575
- Periodontitis, and diabetes mellitus, 585–586
treatment of, 586
cardiovascular disease and, 575–577
epidemiologic studies in, 576, 578–579, 580, 581
treatment of, 577
low birth weight and, 586–590
preterm birth and, 586–590
rheumatoid arthritis and, 584–585
treatment of, 585
- Pneumocystis carinii pneumonia, HIV disease and, 474–475
- Pneumonia, and oral bacteria, 583–584
therapeutic consequences of, 584
community-acquired, 583
hospital-acquired, 583–584
- Preterm birth, periodontitis and, 586–590
- Prion diseases. See *Encephalopathy(ies)*, *transmissible spongiform*.

- Prions, and human transmissible spongiform encephalopathies, **493–516**
description of, 493, 505
in human trigeminal nerve and oral tissue, 504–505
locations of, detection of, animal studies of, 496
transmission by dental route, animal studies of, 496
- Pyrazinamide, in tuberculosis, 457
side effects of, 462
- Pyrogenic reactions, 551

R

-
- Ramsay-Hunt syndrome, 523
- Retroviruses, 541
- Reye's syndrome, 522
- Rheumatoid arthritis, and periodontitis, 584–585
treatment of, 585
- Rifampin, in tuberculosis, 457
side effects of, 461–462
- RNA oncogenic viruses, 541
- Roseola, human herpesvirus-6B and, 527

S

-
- Salivary glands, dysfunction of, in HIV disease, 477–482
- Scrapie, 493, 495
- Scrapielike spongiform encephalopathy, 495
- Screening enzyme immunoassay, 470
- Spongiform encephalopathies, transmissible. See *Encephalopathy(ies)*, *transmissible spongiform*.
- Squamous cell carcinoma, human papillomavirus and, 536, 538
- Streptomycin, in tuberculosis, 457
side effects of, 462
- Systemic diseases, oral infections and, **575–598**

T

-
- Tobacco use, carcinomas associated with, 537–538
- Transfusion-transmitted virus, 443

Transmissible spongiform encephalopathies. See *Encephalopathy(ies), transmissible spongiform*.

Trismus, associated with noma, 563, 567, 568

Tuberculin, old, 455

Tuberculin skin testing, 456

Tuberculosis, **449–465**
 as global, 449
 extrapulmonary, manifestations of, 452
 granulomatous inflammation in, 451
 history of, 449
 HIV disease and, 454–455, 475
 incidence of, 449–450
 management of, 455–458
 management of dental patient with, 458–462
 miliary, 453
 of head and neck, 453
 oral manifestations of, 453–454
 pulmonary manifestations of, 451
 reactivation of, 451–452
 secondary, 451
 testing for, 456
 transmission of, 450–453
 barrier techniques to prevent, 460–461
 Centers for Disease Control and, 458
 dental workers and, 459–460
 dentist-to-patient, 460
 in health care facility, risk categories for, 460

treatment of, 456–458
 vaccination in, 455

V

Vaccination, in tuberculosis, 455

Varicella, 522

Varicella zoster virus, 522–524

Verrucous carcinoma, human papillomavirus and, 537–538

Virus(es), and neoplastic growth, **533–543**
 classification of, 533–534
 DNA oncogenic, 535–541
 RNA oncogenic, 541

W

Water bacteria, gram-negative heterotrophic, 546

Water systems, dental unit, contamination of, 548–553
 methods to control, 553
 sources of biofilm in, 548

Waterlines, dental, and health, 548–553
 biofilms in, 547–548
 diseases caused by, 550
 portals of entry of, 550
 design of, biofilms and, 547–548
 organisms in, potential pathogenicity of, 549
 waterborne pathogens and, **545–557**

World Health Organization noma network, noma and, 569–570